DK175366B1 - Fremgangsmåde til fremstilling af biologisk aktiv human vævstype-plasminogenaktivator - Google Patents
Fremgangsmåde til fremstilling af biologisk aktiv human vævstype-plasminogenaktivator Download PDFInfo
- Publication number
- DK175366B1 DK175366B1 DK198702881A DK288187A DK175366B1 DK 175366 B1 DK175366 B1 DK 175366B1 DK 198702881 A DK198702881 A DK 198702881A DK 288187 A DK288187 A DK 288187A DK 175366 B1 DK175366 B1 DK 175366B1
- Authority
- DK
- Denmark
- Prior art keywords
- medium
- plasminogen activator
- human tissue
- type plasminogen
- cell
- Prior art date
Links
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims description 33
- 230000008569 process Effects 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title description 5
- 239000000306 component Substances 0.000 claims abstract description 32
- 238000004113 cell culture Methods 0.000 claims abstract description 16
- 238000001914 filtration Methods 0.000 claims abstract description 15
- 230000001627 detrimental effect Effects 0.000 claims abstract description 7
- 239000012533 medium component Substances 0.000 claims abstract description 4
- 238000011084 recovery Methods 0.000 claims abstract description 4
- 239000002609 medium Substances 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 54
- 239000000725 suspension Substances 0.000 claims description 19
- 238000009295 crossflow filtration Methods 0.000 claims description 13
- 239000006285 cell suspension Substances 0.000 claims description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 12
- 230000012010 growth Effects 0.000 claims description 11
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 9
- 239000012510 hollow fiber Substances 0.000 claims description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000004114 suspension culture Methods 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- 108010022394 Threonine synthase Proteins 0.000 claims description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 2
- 102000019400 Tissue-type plasminogen activator Human genes 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 22
- 230000009931 harmful effect Effects 0.000 abstract description 13
- 102000001938 Plasminogen Activators Human genes 0.000 abstract description 6
- 108010001014 Plasminogen Activators Proteins 0.000 abstract description 6
- 229940127126 plasminogen activator Drugs 0.000 abstract description 6
- 238000012258 culturing Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 230000007717 exclusion Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 22
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- 239000012091 fetal bovine serum Substances 0.000 description 14
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 9
- 230000002939 deleterious effect Effects 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 239000012930 cell culture fluid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- -1 neuramididase Substances 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000047823 human PLAT Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87164286A | 1986-06-06 | 1986-06-06 | |
| US87164286 | 1986-06-06 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK288187D0 DK288187D0 (da) | 1987-06-04 |
| DK288187A DK288187A (da) | 1987-12-07 |
| DK175366B1 true DK175366B1 (da) | 2004-09-13 |
Family
ID=25357832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198702881A DK175366B1 (da) | 1986-06-06 | 1987-06-04 | Fremgangsmåde til fremstilling af biologisk aktiv human vævstype-plasminogenaktivator |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5053334A (cs) |
| EP (1) | EP0248675B1 (cs) |
| JP (1) | JPS6332484A (cs) |
| KR (1) | KR930002888B1 (cs) |
| AT (1) | ATE75775T1 (cs) |
| AU (1) | AU601984B2 (cs) |
| DD (1) | DD257087A5 (cs) |
| DE (2) | DE3718939C2 (cs) |
| DK (1) | DK175366B1 (cs) |
| ES (1) | ES2032444T3 (cs) |
| FI (1) | FI91886C (cs) |
| FR (1) | FR2599625B1 (cs) |
| GB (1) | GB2191493B (cs) |
| GR (1) | GR3005245T3 (cs) |
| HU (1) | HU205171B (cs) |
| IE (1) | IE60485B1 (cs) |
| IL (1) | IL82746A (cs) |
| NO (1) | NO170595C (cs) |
| NZ (1) | NZ220547A (cs) |
| PT (1) | PT84991B (cs) |
| ZA (1) | ZA874054B (cs) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL82746A (en) * | 1986-06-06 | 1994-10-07 | Genentech Inc | Process for producing biologically active tissue-type plasminogen activator |
| JP2576200B2 (ja) * | 1988-03-09 | 1997-01-29 | 味の素株式会社 | 生理活性タンパク質の製造法 |
| EP0338716A3 (en) * | 1988-04-21 | 1990-04-11 | Berlex Laboratories, Inc. | Method and system for the production of non-degraded proteins from mammalian cells |
| DE3829244A1 (de) * | 1988-08-29 | 1990-03-01 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von einkettigem t-pa |
| EP0391080A3 (de) * | 1989-03-07 | 1990-11-07 | Roche Diagnostics GmbH | Verfahren zur Herstellung von zweikettigem t-PA |
| GB2249099B (en) * | 1990-09-26 | 1995-05-03 | Squibb & Sons Inc | Squalene synthetase |
| US5677184A (en) * | 1994-04-19 | 1997-10-14 | Takeda Chemical Industries, Ltd. | CHO cells that express human LH-RH receptor |
| US6077940A (en) | 1997-12-24 | 2000-06-20 | Genentech, Inc. | Free solution ligand interaction molecular separation method |
| KR20050006147A (ko) | 2002-04-08 | 2005-01-15 | 밀레늄 바이올로직스 인코포레이티드 | 자동화된 조직 엔지니어링 시스템 |
| CN104263700A (zh) | 2006-07-14 | 2015-01-07 | 帝斯曼知识产权资产管理有限公司 | 改进的细胞培养方法 |
| EP2188371B1 (en) * | 2007-08-09 | 2017-12-20 | Wyeth LLC | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| EP2525899A1 (en) * | 2010-01-22 | 2012-11-28 | Lonza Walkersville, Inc. | High yield method and apparatus for volume reduction and washing of therapeutic cells using tangential flow filtration |
| US10934519B2 (en) | 2011-07-29 | 2021-03-02 | Global Life Sciences Solutions Usa Llc | Systems, methods and control laws for cell harvesting |
| US9695393B2 (en) * | 2012-08-20 | 2017-07-04 | Terumo Bct, Inc. | Concentrating components of fluid circulated through a cell growth chamber |
| EP3662056A2 (en) | 2017-09-01 | 2020-06-10 | Lonza Walkersville, Inc. | End-to-end cell therapy automation |
| CA3123449A1 (en) | 2018-12-21 | 2020-06-25 | Lonza Walkersville, Inc. | Automated production of viral vectors |
| IL284214B2 (en) | 2018-12-21 | 2025-03-01 | Octane Biotech Inc | Carousel for modular biologic production units |
| CA3123458A1 (en) | 2018-12-28 | 2020-07-02 | Octane Biotech Inc. | Cell culture and tissue engineering systems with controlled environmental zones |
| KR20210125510A (ko) | 2019-02-08 | 2021-10-18 | 론자 워커스빌 아이엔씨. | 자동화 생물반응기에서 사용하기 위한 세포 농축 방법 및 장치 |
| EP4048773A4 (en) | 2019-10-24 | 2024-01-03 | Octane Biotech Inc. | CELL CULTURE CHAMBER WITH IMPROVED CELL CONTACT SURFACES |
| CA3159567A1 (en) | 2019-11-11 | 2021-05-20 | Lonza Walkersville, Inc. | Quality control methods for automated cell processing |
| CA3224150A1 (en) | 2021-07-02 | 2023-01-05 | Combangio, Inc. | Processes for making and using a cellular fibronectin composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3904480A (en) * | 1972-10-24 | 1975-09-09 | Lilly Co Eli | Enhanced production of plasminogen activator |
| JPS5329985A (en) * | 1976-08-27 | 1978-03-20 | Kanegafuchi Chem Ind Co Ltd | High concentration culturing of yeast |
| JPS5571496A (en) * | 1978-11-24 | 1980-05-29 | Asahi Chem Ind Co Ltd | Preparation of living substance |
| US4409331A (en) * | 1979-03-28 | 1983-10-11 | Damon Corporation | Preparation of substances with encapsulated cells |
| US4232124A (en) * | 1979-04-23 | 1980-11-04 | Mann George F | Method of producing plasminogen activator |
| DE3015699C2 (de) * | 1979-04-26 | 1982-07-15 | Asahi Kasei Kogyo K.K., Osaka | Herstellung eines Plasminogen-Aktivators |
| JPS5642584A (en) * | 1979-09-18 | 1981-04-20 | Asahi Chem Ind Co Ltd | Cell cultivation method |
| US4420398A (en) * | 1981-08-13 | 1983-12-13 | American National Red Cross | Filteration method for cell produced antiviral substances |
| GR79202B (cs) * | 1982-05-05 | 1984-10-22 | Genentech Inc | |
| JPS5951220A (ja) * | 1982-08-02 | 1984-03-24 | Asahi Chem Ind Co Ltd | 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤 |
| US4537860A (en) * | 1982-12-08 | 1985-08-27 | Monsanto Company | Static cell culture maintenance system |
| NZ206699A (en) * | 1982-12-30 | 1989-08-29 | Bio Response Inc | Process for the production of serum independent cell lines |
| AU572108B2 (en) * | 1983-01-19 | 1988-05-05 | Genentech Inc. | Human tpa production using vectors coding for dhfr protein |
| JPS59121172U (ja) * | 1983-02-04 | 1984-08-15 | ミネソタ・マイニング・アンド・マニユフアクチユアリング・コンパニ− | ケーブル電線被覆の剥離部分のカバー装置 |
| US4546083A (en) * | 1983-04-22 | 1985-10-08 | Stolle Research & Development Corporation | Method and device for cell culture growth |
| PH22337A (en) * | 1983-11-21 | 1988-08-12 | Ciba Geigy Ag | Synthesis of fibrinolytic agents by yeast |
| US4740461A (en) * | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4888115A (en) * | 1983-12-29 | 1989-12-19 | Cuno, Incorporated | Cross-flow filtration |
| US4757005A (en) * | 1984-04-19 | 1988-07-12 | Miles Inc. | Method and cell line for obtaining plasminogen activators |
| EP0215923B1 (en) * | 1985-03-22 | 1990-12-27 | Chiron Corporation | Expression of tpa in mammalian cells |
| AU593264B2 (en) * | 1985-07-10 | 1990-02-08 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Chromosomal DNA sequence, expression vector for human tissue plasminogen activating factor, cultured cells transfected with same and method of producing said activating factor |
| AU606582B2 (en) * | 1985-09-06 | 1991-02-14 | Codon | Methods for the recovery of tissue plasminogen activator |
| JPH07110232B2 (ja) * | 1985-10-14 | 1995-11-29 | 株式会社日立製作所 | 遺伝子組換え大腸菌の遺伝子生産物を採取する方法および装置 |
| IL82746A (en) * | 1986-06-06 | 1994-10-07 | Genentech Inc | Process for producing biologically active tissue-type plasminogen activator |
-
1987
- 1987-06-02 IL IL8274687A patent/IL82746A/en not_active IP Right Cessation
- 1987-06-02 PT PT84991A patent/PT84991B/pt unknown
- 1987-06-03 NZ NZ220547A patent/NZ220547A/en unknown
- 1987-06-03 HU HU872536A patent/HU205171B/hu unknown
- 1987-06-04 DK DK198702881A patent/DK175366B1/da not_active IP Right Cessation
- 1987-06-04 KR KR1019870005638A patent/KR930002888B1/ko not_active Expired - Lifetime
- 1987-06-05 IE IE150487A patent/IE60485B1/en not_active IP Right Cessation
- 1987-06-05 GB GB8713267A patent/GB2191493B/en not_active Revoked
- 1987-06-05 ES ES198787304995T patent/ES2032444T3/es not_active Expired - Lifetime
- 1987-06-05 DD DD30357587A patent/DD257087A5/de unknown
- 1987-06-05 NO NO872395A patent/NO170595C/no unknown
- 1987-06-05 DE DE3718939A patent/DE3718939C2/de not_active Expired - Lifetime
- 1987-06-05 ZA ZA874054A patent/ZA874054B/xx unknown
- 1987-06-05 DE DE8787304995T patent/DE3778758D1/de not_active Expired - Lifetime
- 1987-06-05 FI FI872526A patent/FI91886C/fi not_active IP Right Cessation
- 1987-06-05 EP EP87304995A patent/EP0248675B1/en not_active Expired - Lifetime
- 1987-06-05 FR FR878707905A patent/FR2599625B1/fr not_active Expired - Lifetime
- 1987-06-05 AT AT87304995T patent/ATE75775T1/de not_active IP Right Cessation
- 1987-06-05 AU AU73872/87A patent/AU601984B2/en not_active Expired
- 1987-06-05 JP JP62142121A patent/JPS6332484A/ja active Granted
-
1990
- 1990-05-09 US US07/522,073 patent/US5053334A/en not_active Expired - Lifetime
-
1992
- 1992-07-21 GR GR920401579T patent/GR3005245T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175366B1 (da) | Fremgangsmåde til fremstilling af biologisk aktiv human vævstype-plasminogenaktivator | |
| Bowman et al. | Primary culture of microvascular endothelial cells from bovine retina: selective growth using fibronectin coated substrate and plasma derived serum | |
| US4533634A (en) | Tissue culture medium | |
| Lillie et al. | Fine structure of subcultivated stratified squamous epithelium grown on collagen rafts | |
| NO320952B1 (no) | Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl | |
| CA2328084C (en) | Viral production process | |
| PT751988E (pt) | Producao e isolamento altamente eficientes de particulas virais | |
| HU226139B1 (en) | Medium for preserving biological materials | |
| EP0072864A1 (en) | Tissue culture medium | |
| JP6282467B2 (ja) | タンパク質を生産するための方法 | |
| Baker et al. | Effect of the amino acids and dialyzable constituents of embryonic tissue juice on the growth of fibroblasts | |
| WO1989011529A1 (en) | Bioreactor device | |
| Wilson et al. | [18] Preparation and maintenance of adrenal medullary chromaffin cell cultures | |
| CA1198993A (en) | Tissue culture and cell growth promoting material and its method of manufacture | |
| NO322527B1 (no) | Fremgangsmate for rensing av rekombinant Desmodus rotundus-spyttplasminogenaktivator (rDSPA α 1) fra et biologisk medium. | |
| Güttler et al. | Factors affecting the lactate dehydrogenase isoenzyme pattern of cultured kidney-cortex cells | |
| CN114561344A (zh) | 可提高干细胞免疫调控能力的无血清培养基及制备方法和应用 | |
| JP2879906B2 (ja) | プロコラゲナーゼの製造方法 | |
| CN116121183A (zh) | M4完全培养基在宫血间充质干细胞培养中的应用 | |
| JPS61126031A (ja) | コロニ−形成刺激因子の製造法 | |
| AU8338082A (en) | Tissue culture medium | |
| EMBRYONIC et al. | 1 Carrel, A., J. Exp. Med., 1912, xv, 516; 1913, xvii, 14; 1914, xx, 1. Fischer, A., J. Exp. Med., 1922, xxxv, 367. Ebeling, AH, J. Exp. Med., 1922, xxxv, 755. Carrel, A., and Ebeling AH, J. Exp. Med., 1923, xxxviii, 487. Ebeling, A. Н. | |
| JPH0556775A (ja) | 細胞培養用担体 | |
| JPH05252951A (ja) | プロコラゲナーゼの製造方法 | |
| JPS58146278A (ja) | ウロキナ−ゼの大量製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |